2023/08/09 更新

写真a

イケダ　タケシ
池田　健
Takeshi Ikeda
所属
付属病院 総合診療科 助教
職名
助教
外部リンク

研究分野

  • ライフサイエンス / 循環器内科学

論文

  • Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: The EMBODY trial

    Wataru Shimizu, Yoshiaki Kubota, Yu Hoshika, Kosuke Mozawa, Shuhei Tara, Yukichi Tokita, Kenji Yodogawa, Yu Ki Iwasaki, Takeshi Yamamoto, Hitoshi Takano, Yayoi Tsukada, Kuniya Asai, Masaaki Miyamoto, Yasushi Miyauchi, Eitaro Kodani, Masahiro Ishikawa, Mitsunori Maruyama, Michio Ogano, Jun Tanabe, Reiko Shiomura, Isamu Fukuizumi, Junya Matsuda, Satsuki Noma, Hideto Sangen, Hidenori Komiyama, Yoichi Imori, Shunichi Nakamura, Jun Nakata, Hideki Miyachi, Gen Takagi, Takahiro Todoroki, Takeshi Ikeda, Tomoyo Miyakuni, Ayaka Shima, Masato Matsushita, Hirotake Okazaki, Akihiro Shirakabe, Nobuaki Kobayashi, Masamitsu Takano, Yoshihiko Seino, Yugo Nishi, Keishi Suzuki, Junsuke Shibuya, Tsunenori Saito, Hiroyuki Nakano, Morisawa Taichirou, Erito Furuse, Kenji Nakama, Yusuke Hosokawa, Ippei Tsuboi, Hidekazu Kawanaka

    Cardiovascular Diabetology   19 ( 1 )   2020年9月

    　詳細を見る

    掲載種別：研究論文（学術雑誌）  

    © 2020 The Author(s). Background: Protection from lethal ventricular arrhythmias leading to sudden cardiac death (SCD) is a crucial challenge after acute myocardial infarction (AMI). Cardiac sympathetic and parasympathetic activity can be noninvasively assessed using heart rate variability (HRV) and heart rate turbulence (HRT). The EMBODY trial was designed to determine whether the Sodium-glucose cotransporter 2 (SGLT2) inhibitor improves cardiac nerve activity. Methods: This prospective, multicenter, randomized, double-blind, placebo-controlled trial included patients with AMI and type 2 diabetes mellitus (T2DM) in Japan; 105 patients were randomized (1:1) to receive once-daily 10-mg empagliflozin or placebo. The primary endpoints were changes in HRV, e.g., the standard deviation of all 5-min mean normal RR intervals (SDANN) and the low-frequency-to-high-frequency (LF/HF) ratio from baseline to 24 weeks. Secondary endpoints were changes in other sudden cardiac death (SCD) surrogate markers such as HRT. Results: Overall, 96 patients were included (46, empagliflozin group; 50, placebo group). The changes in SDANN were + 11.6 and + 9.1 ms in the empagliflozin (P = 0.02) and placebo groups (P = 0.06), respectively. Change in LF/HF ratio was - 0.57 and - 0.17 in the empagliflozin (P = 0.01) and placebo groups (P = 0.43), respectively. Significant improvement was noted in HRT only in the empagliflozin group (P = 0.01). Whereas intergroup comparison on HRV and HRT showed no significant difference between the empagliflozin and placebo groups. Compared with the placebo group, the empagliflozin group showed significant decreases in body weight, systolic blood pressure, and uric acid. In the empagliflozin group, no adverse events were observed. Conclusions: This is the first randomized clinical data to evaluate the effect of empagliflozin on cardiac sympathetic and parasympathetic activity in patients with T2DM and AMI. Early SGLT2 inhibitor administration in AMI patients with T2DM might be effective in improving cardiac nerve activity without any adverse events. Trial Registration: The EMBODY trial was registered by the UMIN in November 2017 (ID: 000030158). UMIN000030158; https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000034442.

    DOI： 10.1186/s12933-020-01127-z

    Scopus

    PubMed

    researchmap

  • Acute myocarditis associated with coxsackievirus B4 mimicking influenza myocarditis: electron microscopy detection of causal virus of myocarditis. 国際誌

    Takeshi Ikeda, Tsunenori Saito, Gen Takagi, Shigeru Sato, Hitoshi Takano, Yusuke Hosokawa, Meiso Hayashi, Kuniya Asai, Masahiro Yasutake, Kyoichi Mizuno

    Circulation   128 ( 25 )   2811 - 2   2013年12月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DOI： 10.1161/CIRCULATIONAHA.112.000602

    PubMed

    researchmap